Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients

Makoto Ishikawa1,2
Takeshi Yoshitomi1

1Department of Ophthalmology, Akita University Faculty of Medicine, Akita, Japan; 2Department of Ophthalmology, Ogachi Central Hospital, Akita, Japan

Purpose: To study the effect of the concomitant use of brinzolamide and latanoprost on the 24-hour variation in intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients first treated with timolol and latanoprost.

Methods: We studied 30 eyes from 30 POAG patients previously treated with latanoprost monotherapy. After a washout of four weeks in both eyes, all patients were treated with 0.5% timolol and latanoprost. Three months after the initiation of treatment with timolol and latanoprost, the 24-hour IOP variation was measured. Thereafter, all patients were treated with concomitant 1% brinzolamide and latanoprost. Three months after changing the therapeutic regimen, the 24-hour IOP variation was measured a second time. Latanoprost was administered once a day, and timolol and brinzolamide were twice a day. IOP was measured with a noncontact tomometer.

Results: On treatment with brinzolamide and latanoprost, a significant decrease in IOP compared to timolol and latanoprost was observed at all time points except at 3 PM and 6 PM. As a group, the patients had a significantly lower diurnal mean IOP and nocturnal mean IOP during treatment with brinzolamide and latanoprost than with timolol and latanoprost.

Conclusions: Treatment of POAG with a combination of brinzolamide and latanoprost demonstrated improved hypotensive effects compared with timolol and latanoprost during a 24-hour period.

Keywords: circadian intraocular pressure, adverse effects, timolol, brinzolamide

Introduction

The most important risk factor in glaucoma is poorly controlled ocular hypertension. Therefore, a therapy that lowers intraocular pressure (IOP) is the most reliable approach for glaucoma.

Timolol, a relatively nonselective β-blocker, lowers IOP by suppressing the production of aqueous humor and is considered to be among the most effective glaucoma medications developed over the past 20 years. However, it is likely that timolol may cause adverse reactions in the cardiovascular and respiratory systems, and hence, a carefully obtained medical history is necessary to identify any predisposing condition.

Prostaglandin F2α analogs (PGA) are a class of IOP-lowering medications that reduce IOP by increasing the aqueous humor outflow rate via the uveoscleral route. The PGA latanoprost has a favorable IOP-lowering effect and causes no serious systemic adverse reactions; consequently, it has been widely used as a first-line glaucoma
medication. However, PGA has several local side effects such as iris pigmentation, poliosis, eyelid pigmentation, etc. Occasionally, patients cannot attain their target IOP and either switch to another PGA and/or require adjunctive therapy. Unfixed or fixed combinations of latanoprost and timolol have been demonstrated to effectively lower IOP.

Brinzolamide is a more recently developed carbonic anhydrase inhibitor. The effects of coadministration of brinzolamide with latanoprost have been explored in few studies. Brinzolamide lowers IOP by suppressing the production of aqueous humor. Indeed, brinzolamide monotherapy appears to have a weaker IOP-lowering effect than β-blocker monotherapy; however, brinzolamide is expected to exert a further IOP-lowering effect when added to a PGA, like other carbonic anhydrase inhibitors. Nakamoto and Yasuda reported that when single-agent latanoprost was compared to concomitant treatment with brinzolamide and latanoprost, the combination therapy exerted a greater nocturnal IOP-lowering effect. Additionally, it has been reported that the concomitant use of PGA 0.004% travoprost and 0.1% brinzolamide is superior in its IOP-lowering effect to the fixed combination (Xalacom; Pfizer, New York, NY, USA) of 0.005% latanoprost and 0.5% timolol.

In this single-arm study, patients with primary open-angle glaucoma (POAG) were coadministered timolol and latanoprost for three months, after which the therapy was changed to brinzolamide and latanoprost in order to investigate potential changes in circadian IOP variation. In addition, the cardiovascular safety of these two combination regimens was also investigated.

**Patients and methods**

**Inclusion and exclusion criteria**

Patients with POAG receiving outpatient care at the Department of Ophthalmology, Ogachi Central Hospital, Akita, Japan, were enrolled. The study was carried out in accordance with the World Medical Association’s Declaration of Helsinki and was approved by the ethical review board at Ogachi Central Hospital.

Patients were selected from those who had latanoprost monotherapy for over three months. Patients were required to provide written informed consent; have a typical glaucomatous optic disc finding with a corresponding visual field defect in both eyes; and lack any eye, nasal sinus, or systemic disease affecting the optic nerve. Additional exclusion criteria included heart disease, respiratory disease, past history of renal disease, past history of serious corneal lesion or uveitis, past history of intraocular surgery or laser treatment, systemic use of a carbonic anhydrase inhibitor or β-blocker, corneal endothelial cell count of less than 1,500 cells/mm², and ineligibility to participate in this study as judged by the investigators. Ocular hypertension of greater than 25 mmHg while using latanoprost monotherapy was also excluded from this study in order to avoid the risk of further elevation of IOP.

**Study design**

Patients had a four-week washout period, in which they discontinued latanoprost use. Patients then topically applied 0.5% timolol to both eyes twice daily (8 AM and 8 PM) and latanoprost once daily (8 PM). Patients were instructed to use forced eyelid closure for three minutes, and keep a time interval of five minutes between topical applications when applying the drugs at 8 PM. All patients visited the hospital every four weeks. A questionnaire asking about current use of eye drops was distributed to all patients at the time of their regular clinical visits, and their adherence to medication was evaluated. Three months after the start of treatment, the patients were hospitalized, during which their 24-hour circadian IOP variation was measured as follows: IOP was measured three times at each time point in the sitting position with a noncontact tonometer (PULS AIR 2000; Keeler Co, Windsor, England) in three-hour intervals for a total of eight times a day (6 AM, 9 AM, 12 PM, 3 PM, 6 PM, 9 PM, 12 AM, 3 AM). At night, patients were awakened and allowed to relax for 10 minutes, and then IOP was measured with the patient sitting on the bed. According to a previous report, measurement was calculated three times and averaged if the difference in IOP measurement was 3 mmHg or less. When the difference was greater than 3 mmHg, the IOP was measured until the difference in three consecutive values was 3 mmHg or less.

Immediately following this series of measurements, 1% brinzolamide was substituted for timolol, and co-administration with latanoprost was continued for three months. Brinzolamide was applied to both eyes twice daily (8 AM and 8 PM) and latanoprost once daily (8 PM). As before, the patients were instructed to use forced eyelid closure for three minutes, along with a five-minute time interval between topical applications when applying the drugs at 8 PM. After three months of treatment, the patients were hospitalized a second time, during which their circadian IOP variation was measured again. Blood pressure and pulse rate were measured in triplicate between 9 AM and 10 AM on each hospitalization day.

**Statistical analysis**

From IOP measurements during hospitalization, the following outcomes were calculated: (1) 24-hour mean IOP
(mean value of IOP at all time points), (2) diurnal mean IOP (mean value of IOP at 9 AM, 12 PM, and 3 PM), and (3) nocturnal IOP (mean value of IOP at 9 PM, 12 AM, and 3 AM). Percent reduction in IOP was calculated by using the following formula:

\[
\text{Percent reduction in IOP} = \left[ \frac{\text{IOP at enrollment} - \text{IOP after transition}}{\text{IOP at enrollment}} \right] \times 100
\]

Systolic blood pressure, diastolic blood pressure, mean blood pressure, and pulse rate were compared before and after the transition from timolol to brinzolamide.

Statistical analyses using right eye of each patient were conducted using two-sided paired t-test with a significance level of 5%.

### Glaucoma criteria

Glaucoma diagnosis was based on optic disc appearance, including cup-to-disc ratio; rim width; nerve fiber layer defect; the results of the Humphrey Field Analyzer examination; and clinical records from screening and definitive examinations. The criteria for glaucoma diagnosis were based on the criteria of previous population studies, described in Table 1. First, when the vertical cup-to-disc ratio of the optic nerve head was 0.7 or more; or the rim width at the superior portion (the 11 to 1 o’clock position) or inferior portion (the 5 to 7 o’clock position) was 0.1 or less of disc diameter; or the difference in the vertical cup-to-disc ratio was 0.2 or more between both eyes; or a nerve fiber layer defect was found – the eye was diagnosed with glaucoma (Category 1). Next, when the vertical cup-to-disc ratio was 0.9 or more; or the rim width at the superior portion (the 11 to 1 o’clock position) or inferior portion (the 5 to 7 o’clock position) 0.05 or less; or the difference of the vertical cup-to-disc ratio was 0.3 or more between both eyes; or a nerve fiber layer defect was found – the eye was diagnosed with glaucoma suspect (Glaucoma suspect). In the definitive diagnosis, anomalous discs, including tilted discs, were carefully excluded.

### Results

Thirty patients were enrolled in this study. Fifty percent (n = 15) of the patients were male. The mean age of the total patient population was 70.2 ± 10.2 years old. No patients discontinued treatment or withdrew from the study. Prior to enrollment, all participants were treated with 0.005% latanoprost monotherapy, which was typically applied to both eyes once daily at night for 5.5 ± 2.0 months; it produced 20%–33% reduction in IOP (the mean IOP range was 16.8 ± 3.2 mmHg). The minimum untreated IOP was 17 mmHg, and the average untreated IOP was 18.9 ± 5.6 mmHg. The visual field mean deviation (MD) at enrollment was −4.2 ± 3.2 dB on the Humphrey Field Analyzer, Center 30–2 Program.

IOP was analyzed using the data from the right eye of the enrolled patients. The comparison of mean IOP

### Table 1 The criteria for primary open-angle glaucoma diagnosis

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
</table>
| **Category 1** | The vertical cup-to-disc ratio of the optic nerve head is 0.7 or more; or the rim width at the superior portion (11–1 hours) or the inferior portion (5–7 hours) is 0.1 or less of the disc diameter; or the difference of the vertical cup-to-disc ratio is 0.2 or more between both eyes; or a nerve fiber layer defect was found; and the hemifield-based visual field abnormality was compatible with optic disc appearance or nerve fiber layer defect
| **Category 2** | When the visual field test result is not reliable or available, the cup-to-disc ratio of the optic nerve head is 0.9 or more; or the rim width at the superior portion (11–1 hours) or the inferior portion (5–7 hours) is 0.05 or less of the disc diameter; or the difference of the vertical cup-to-disc ratio is 0.3 or more between both eyes
| **Glaucoma suspect** | When the cup-to-disc ratio of the optic nerve head is 0.7 or more but less than 0.9; or the rim width at the superior portion (11–1 hours) or the inferior portion (5–7 hours) is 0.1 or less but more than 0.05 of the disc diameter; or the difference of the vertical cup-to-disc ratio is 0.2 or more but less than 0.3 between both eyes; or a nerve fiber layer defect is found; and the visual field test result is not reliable or available or does not show hemifield-based compatible defect; the eye is diagnosed with suspected glaucoma
between treatment regimens at each time point showed that a significant IOP reduction was observed after the transition to brinzolamide and latanoprost at all time points except at 3 PM and 6 PM (Figure 1, \( P < 0.01 \)). The 24-hour mean IOP with timolol and latanoprost was 12.6 ± 2.4 mmHg compared to 11.9 ± 2.5 mmHg after the change in treatment to brinzolamide and latanoprost. This represents a statistically significant difference (Figure 2, \( P < 0.01 \)) that translated into a 5.8% ± 1.5% reduction in IOP. Diurnal mean IOP was 12.6 ± 2.3 mmHg before the transition, and 11.8 ± 2.3 mmHg after the transition (Figure 2, \( P < 0.05 \)) for a 7.3% ± 1.9% reduction in IOP. The nocturnal mean IOP was 13.1 ± 3.4 mmHg before the transition and 11.7 ± 3.1 mmHg after the transition, showing a statistically significant reduction in IOP (Figure 2, \( P < 0.001 \)) of 9.6% ± 1.9%. The maximum mean IOP was 15.0 ± 3.9 mmHg with timolol and latanoprost therapy and 14.1 ± 4.2 mmHg with brinzolamide and latanoprost therapy, showing a significant reduction in IOP of 6.1% ± 2.3% (Figure 3, \( P < 0.05 \)). The minimum mean IOP was 10.5 ± 1.9 mmHg before the transition and 10.2 ± 1.7 mmHg after changing the regimen, showing no significant difference between the two regimens (Figure 3). The IOP range was 4.3 ± 2.4 mmHg before the change from timolol to brinzolamide and 3.9 ± 2.5 mmHg after the transition, showing no statistically significant difference (Figure 3).

Based on the questionnaire on the use of eye drops, patient adherence was calculated to be least 90% in all cases for each medication.

No statistically significant difference in systolic blood pressure, diastolic blood pressure, or mean blood pressure was observed between the treatment regimens (Table 2). The pulse rate was significantly higher after the transition to brinzolamide and latanoprost therapy (65.7 ± 5.7 vs 72.9 ± 6.7 beats/minute, \( P < 0.05 \); Table 2).

Adverse events observed during the study are presented in Table 3. Mild conjunctival hyperemia (one patient) and corneal epithelial disorder (one patient) were observed while taking timolol and latanoprost, but these symptoms disappeared after transitioning to brinzolamide and latanoprost. Taste perversion (one patient) was observed after the transition to brinzolamide and latanoprost, but it was present only transiently and required no treatment.

**Discussion**

Concomitant treatment with timolol and latanoprost was conducted for three months in patients with open-angle glaucoma, followed by concomitant treatment with brinzolamide

![Figure 1](https://www.dovepress.com/)

**Figure 1** Comparison of mean intraocular pressure levels (millimeters of mercury) for timolol and latanoprost versus brinzolamide and latanoprost across a 24-hour time period (n = 30).

**Notes:** *\( P < 0.05 \), **\( P < 0.01 \), ***\( P < 0.001 \), mean ± SE (paired t-test).

**Abbreviations:** IOP, intraocular pressure; SE, standard error.
Figure 2 Comparison of 24-hour mean IOP (averaged across all time points), diurnal mean IOP (9 AM, 12 PM, and 3 PM), and nocturnal mean IOP (9 PM, 12 AM, and 3 AM) for timolol and latanoprost versus brinzolamide and latanoprost (n = 30).

Notes: *P < 0.05, **P < 0.01, ***P < 0.001, mean ± SE (paired t-test).

Abbreviations: IOP, intraocular pressure; SE, standard error.

Figure 3 Comparison of mean maximum IOP, mean minimum IOP, and mean IOP range for eyes receiving timolol and latanoprost versus brinzolamide and latanoprost (n = 30).

Notes: *P < 0.05, mean ± SE (paired t-test).

Abbreviations: IOP, intraocular pressure; SE, standard error.
Table 2 Comparison of blood pressure and pulse rate before and after changing treatment

<table>
<thead>
<tr>
<th>Blood pressure (mmHg)</th>
<th>Timolol + Latanoprost</th>
<th>Brinzolamide + Latanoprost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic</td>
<td>128.5 ± 15.6</td>
<td>130.1 ± 14.7</td>
</tr>
<tr>
<td>Diastolic</td>
<td>78.1 ± 7.9</td>
<td>79.1 ± 12.6</td>
</tr>
<tr>
<td>Mean</td>
<td>94.5 ± 13.4</td>
<td>95.1 ± 11.9</td>
</tr>
<tr>
<td>Pulse rate (beat/min)</td>
<td>65.7 ± 5.7</td>
<td>72.9 ± 6.7*</td>
</tr>
</tbody>
</table>

Note: *P < 0.05 (paired t-test).

Table 3 Adverse events observed during the study

<table>
<thead>
<tr>
<th>Ocular adverse reactions</th>
<th>Timolol + Latanoprost</th>
<th>Brinzolamide + Latanoprost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjunctival hyperemia</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Corneal epithelial damage</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Systemic adverse reactions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taste perversion</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

Although brinzolamide produced superior IOP-lowering results compared to timolol in this study, we must discuss the following limitation of the present study design. The patients were not randomized into treatment with either brinzolamide and latanoprost or timolol and latanoprost. Thus, the treatment sequence or underlying changes in the disease over time could have affected the results of this study.

In recent years, it has been suggested that glaucomatous optic neuropathy may be caused by a reduction in blood flow in the optic disc because of nocturnal hypotension and heart rate decrease. Hayreh and colleagues reported that when a β-blocker was topically applied to glaucoma patients, nocturnal blood pressure and heart rate were reduced, thereby deteriorating the visual field. For this reason, it may be desirable to use drugs that have minimal effects on the cardiovascular system of glaucoma patients. The merits of brinzolamide include fewer ocular adverse events and no serious systemic adverse reactions.

A previous study has shown that, in contrast to timolol, brinzolamide does not exert any suppressive effect on heart rate. Confocal laser Doppler flowmetry shows the positive blood flow effect of brinzolamide, which increases retinal oxygen saturation in patients with glaucoma. In the current investigation as well, treatment with brinzolamide and latanoprost produced no reduction in heart rate; rather, the mean pulse rate during timolol therapy was decreased compared to brinzolamide. Several population-based epidemiological studies have shown that ocular perfusion pressure (OPP) is a significant risk factor associated with glaucoma incidence. OPP is calculated as the following formula:

\[
OPP = [\text{mean BP} \times (2/3) - \text{IOP}]
\]

In the present study, mean blood pressure, which is directly related to OPP, was similar in the two treatment regimens. However, timolol and latanoprost is considered to induce an increase in OPP because of concomitant significant reduction in IOP.

All three adverse reactions observed in the current study were mild and did not result in discontinuation of treatment. The frequency of ocular and systemic adverse reactions in this study was similar to those in previous reports.

Although it is an applanation tonometer is commonly used, we measured the IOP with a noncontact tonometer in our study because of the inconvenience of our accommodation: the setting of a slit-lamp attached to
applanation tonometer was located far from the bedside of our patients. We were afraid to allow the patients to walk for a distance, especially at midnight, because it is known that the circadian clock is responsible for the temporal organization of several functions, such as heart rate; body temperature; and hormonal release. Therefore, in the present study, we went to the patient bedside to measure the IOP by ourselves.

Conclusions
When taken together, the combination of brinzolamide and latanoprost demonstrated an improved hypotensive effect in open-angle glaucoma patients compared to timolol and latanoprost during a 24-hour period.

Disclosures
The authors report no conflicts of interest or financial support in this work.

References
10. Camras CB, Hedman K; the US Latanoprost Study Group. Rate of temperature; and hormonal release.
13. Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2008;5:1435–1442.
20. Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2008;5:1435–1442.

